HCC Day 2025 in Bern and online, on Feb. 27th 2025.

Swiss Foundation against Liver Cancer

Liver cancer is a frequent disease. Patients with liver cancer have most of the time an underlying chronic liver disease, often without knowing it since the liver is an organ which does not trigger pain. However, it is possible to cure patients from their liver cancer when the diagnosis is done at an early stage. Therefore diagnostic tools for detecting liver cancer are of utmost importance.

Therapeutically great progresses have been realized in the last years, patients have access to more possible treatments. But the treatment of patients with liver cancer is complex.

The Swiss Foundation against Liver Cancer aims at disseminating information about this disease to increase awareness and to support research to improve the diagnosis, therapy and management of patients and families confronted with this disease.

With your help, overcoming liver cancer becomes possible.

Make a donation

Our mission

Research>

Sensitization>

Fund raising>

854'000 New cases of malignant liver cancer per year worldwide

Between 1990 and 2017, the number of diagnostic cases more than doubled worldwide

5th most common tumor in the world

2nd cause of death from cancer

News

Unlocking New Insights in Hepatocellular Carcinoma: An Exclusive Interview with Prof. Andrea Casadei-Gardini

In the ever-evolving landscape of hepatocellular carcinoma (HCC) treatment, every breakthrough brings us closer to improving patient outcomes. We are thrilled to present an exclusive interview with Professor Andrea Casadei-Gardini, a leading expert in oncology, who shares pivotal findings from his recent paper, “Lenvatinib versus Sorafenib Second-Line Therapy in Patients with Hepatocellular Carcinoma Progressed to

Insights into Liver Cancer Management with Professor Ducreux

In our recent podcast lead by Prod. Jean-François Dufour, we had the privilege of speaking with Professor Michel Ducreux, a leading expert in the field of oncology from Paris, France. The discussion focused on the evolving landscape of liver cancer treatment and the latest advancements that are reshaping patient care. Below you will find the

Exploring New Frontiers in Hepatocellular Carcinoma Treatment: Insights from the CheckMate 9DW Trial

In our latest “Ask the Author” session, Professor Peter Galle presented the groundbreaking results of the CheckMate 9DW clinical trial, which explored the efficacy of the combination of nivolumab and ipilimumab versus lenvatinib or sorafenib as first-line treatments for unresectable hepatocellular carcinoma (HCC). Below you will find the video as well as the summary: Background:

HCC Day 2025 in Bern and online, on Feb. 27th 2025.

Swiss Foundation against Liver Cancer

With your help, overcoming liver cancer becomes possible.